▶ Prostap SR DCS (Takeda UK Ltd)
Leuprorelin acetate 3.75 mg Prostap SR DCS 3.75mg powder and
solvent for suspension for injection pre-filled syringes | 1 pre-filled
disposable injection P £75.24 DT = £75.24
l DRUG ACTION Administration of gonadorelin analogues
produces an initial phase of stimulation; continued
administration is followed by down-regulation of
gonadotrophin-releasing hormone receptors, thereby
reducing the release of gonadotrophins (follicle
stimulating hormone and luteinising hormone) which in
turn leads to inhibition of androgen and oestrogen
▶ BY INTRANASAL ADMINISTRATION
▶ Adult (female): 200 micrograms twice daily for
maximum 6 months (do not repeat), one spray in one
nostril in the morning, and one spray in the other
nostril in the evening (starting on days 2–4 of
Pituitary desensitisation before induction of ovulation by
gonadotrophins for in vitro fertilisation (under expert
▶ BY INTRANASAL ADMINISTRATION
▶ Adult: 400 micrograms twice daily, one spray in each
nostril, to be started in early follicular phase (day 2) or,
after exclusion of pregnancy, in midluteal phase (day
21) and continued until down regulation achieved
(usually within 4 weeks) then maintained (usually for
8–12 days) during gonadotrophin administration
(stopping gonadotrophin and nafarelin on
administration of chorionic gonadotrophin at follicular
maturity), discontinue if down-regulation not achieved
l CONTRA-INDICATIONS Undiagnosed vaginal bleeding . use
longer than 6 months in the treatment of endometriosis
l CAUTIONS Patients with metabolic bone disease (decrease
in bone mineral density can occur)
▶ Common or very common Artificial menopause . breast
▶ Uncommon Alopecia . arthralgia . ovarian cyst (may require
▶ Frequency not known Ovarian hyperstimulation syndrome . palpitations . vision blurred
l CONCEPTION AND CONTRACEPTION Non-hormonal, barrier
methods of contraception should be used during entire
treatment period. Pregnancy should be excluded before
treatment, the first dose should be given during
menstruation or shortly afterwards or use barrier
contraception for 1 month beforehand.
l DIRECTIONS FOR ADMINISTRATION Avoid use of nasal
decongestants before and for at least 30 minutes after
treatment; repeat dose if sneezing occurs during or
immediately after administration.
l PATIENT AND CARER ADVICE Patients or carers should be
given advice on how to administer nafarelin nasal spray.
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
CAUTIONARY AND ADVISORY LABELS 10
Nafarelin (as Nafarelin acetate) 200 microgram per
1 dose Synarel 200micrograms/dose nasal spray | 60 dose P £52.43 DT = £52.43
l DRUG ACTION Administration of gonadorelin analogues
produces an initial phase of stimulation; continued
administration is followed by down-regulation of
gonadotrophin-releasing hormone receptors, thereby
reducing the release of gonadotrophins (follicle
stimulating hormone and luteinising hormone) which in
turn leads to inhibition of androgen and oestrogen
Locally advanced non-metastatic prostate cancer as an
alternative to surgical castration | Metastatic prostate
cancer | Adjuvant treatment to radiotherapy in high-risk
localised or locally advanced prostate cancer |
Neoadjuvant treatment prior to radiotherapy in patients
with high-risk localised or locally advanced prostate
cancer | Adjuvant treatment to radical prostatectomy in
patients with locally advanced prostate cancer at high
▶ Adult: 11.25 mg every 3 months
▶ Adult: 11.25 mg every 3 months for maximum
6 months (not to be repeated), to be started during first
Locally advanced non-metastatic prostate cancer as an
alternative to surgical castration | Metastatic prostate
cancer | Adjuvant treatment to radiotherapy in high-risk
localised or locally advanced prostate cancer |
Neoadjuvant treatment prior to radiotherapy in patients
with high-risk localised or locally advanced prostate
cancer | Adjuvant treatment to radical prostatectomy in
patients with locally advanced prostate cancer at high
▶ Adult: 22.5 mg every 6 months
Locally advanced non-metastatic prostate cancer as an
alternative to surgical castration | Metastatic prostate
cancer | Adjuvant treatment to radiotherapy in high-risk
localised or locally advanced prostate cancer |
Neoadjuvant treatment prior to radiotherapy in patients
with high-risk localised or locally advanced prostate
cancer | Adjuvant treatment to radical prostatectomy in
patients with locally advanced prostate cancer at high
▶ Adult: 3 mg every 4 weeks maximum duration of
6 months (not to be repeated), to be started during first
5 days of menstrual cycle continued→
BNF 78 Gonadotrophin responsive conditions 741
Reduction in size of uterine fibroids
▶ Adult: 3 mg every 4 weeks for at least 3 months,
maximum duration of treatment 6 months (not to be
repeated), to be started during first 5 days of menstrual
▶ BY SUBCUTANEOUS INJECTION, OR BY DEEP INTRAMUSCULAR
▶ Adult: 3.75 mg every 4 weeks
Endometriosis | Reduction in size of uterine fibroids
▶ BY SUBCUTANEOUS INJECTION, OR BY DEEP INTRAMUSCULAR
▶ Adult: 3.75 mg every 4 weeks maximum duration of
6 months (not to be repeated), to be started during first
Male hypersexuality with severe sexual deviation
▶ Adult: 11.25 mg every 12 weeks
l CONTRA-INDICATIONS In endometriosis do not use for
longer than 6 months (do not repeat). undiagnosed
SALVACYL ® Severe osteoporosis
GENERAL CAUTIONS Patients with metabolic bone disease
(decrease in bone mineral density can occur)
SALVACYL ® Increased risk of sensitivity to restored
testosterone if treatment interrupted—consider
administration of an antiandrogen before stopping
treatment.transient increase in serum testosterone occurs
on initiation—consider administration of an antiandrogen
▶ Uncommon Alopecia . appetite abnormal . asthma
disorders .tinnitus . vision disorders . vomiting . weight
▶ Frequency not known Angioedema . anxiety . bone disorder . malaise . QT interval prolongation
SIDE-EFFECTS, FURTHER INFORMATION During the initial
stage increased production of testosterone may be
associated with progression of prostate cancer. In
susceptible patients this tumour ‘flare’ may cause spinal
cord compression, ureteric obstruction or increased pain.
l CONCEPTION AND CONTRACEPTION Non-hormonal, barrier
methods of contraception should be used during entire
treatment period. Pregnancy should be excluded before
treatment, the first injection should be given during
menstruation or shortly afterwards or use barrier
contraception for 1 month beforehand.
▶ When used for Prostate cancer Men at risk of tumour ‘flare’
should be monitored closely during the first month of
l DIRECTIONS FOR ADMINISTRATION Rotate injection site to
prevent atrophy and nodule formation.
l PRESCRIBING AND DISPENSING INFORMATION
DECAPEPTYL ® SR 22.5MG Each vial includes an overage to
allow accurate administration of a 22.5 mg dose.
DECAPEPTYL ® SR 3MG Each vial includes an overage to
allow accurate administration of 3 mg dose.
DECAPEPTYL ® SR 11.25MG Each vial includes an overage
to allow accurate administration of an 11.25 mg dose.
l NATIONAL FUNDING/ACCESS DECISIONS
All Wales Medicines Strategy Group (AWMSG) decisions
The All Wales Medicines Strategy Group has advised (March
2017) that triptorelin (Decapeptyl ® SR) is recommended as
an option for use within NHS Wales as an adjuvant
treatment to radiotherapy and as a neoadjuvant treatment
prior to radiotherapy, in patients with high-risk localised
or locally advanced prostate cancer.
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
Powder and solvent for suspension for injection
Triptorelin (as Triptorelin acetate) 3 mg Decapeptyl SR 3mg
powder and solvent for suspension for injection vials | 1 vial P £69.00 DT = £69.00
Triptorelin 11.25 mg Decapeptyl SR 11.25mg powder and solvent for
suspension for injection vials | 1 vial P £207.00 DT = £207.00
Triptorelin (as Triptorelin embonate) 22.5 mg Decapeptyl SR
22.5mg powder and solvent for suspension for injection vials | 1 vial P £414.00 DT = £414.00
▶ Gonapeptyl Depot (Ferring Pharmaceuticals Ltd)
Triptorelin (as Triptorelin acetate) 3.75 mg Gonapeptyl Depot
3.75mg powder and solvent for suspension for injection pre-filled
syringes | 1 pre-filled disposable injection P £81.69 DT = £81.69
Triptorelin 11.25mg Salvacyl 11.25 mg powder and solvent for
suspension for injection vials | 1 vial P £248.00 DT = £207.00
PITUITARY AND HYPOTHALAMIC HORMONES
AND ANALOGUES › ANTI-GONADOTROPHINRELEASING HORMONES
l DRUG ACTION Danazol inhibits pituitary gonadotrophins;
it combines androgenic activity with antioestrogenic and
▶ Adult: 200–800 mg daily in up to 4 divided doses
usually for 3–6 months, dose to be adjusted to achieve
amenorrhoea, in women of child-bearing potential,
treatment should start during menstruation, preferably
742 Gonadotrophin responsive conditions BNF 78
Severe pain and tenderness in benign fibrocystic breast
disease not responding to other treatment
▶ Adult: 300 mg daily in divided doses usually for
3–6 months, in women of child-bearing potential,
treatment should start during menstruation, preferably
▶ Adult: Initially 100–200 mg daily, dose to be reduced
according to response, in women of child-bearing
potential, treatment should start during menstruation,
l UNLICENSED USE Not licensed for use in hereditary
l CAUTIONS Cardiac impairment (avoid if severe). diabetes
mellitus . elderly . epilepsy . history of thrombosis or
thromboembolic disease . hypertension . lipoprotein
disorder. migraine . polycythaemia
l INTERACTIONS → Appendix 1: danazol
l SIDE-EFFECTS Alopecia . aminolevulinic acid synthetase
intolerance . cutaneous lupus erythematosus . depressed
mood . dizziness . embolism and thrombosis . emotional
lability . eosinophilia . epigastric pain . epilepsy
disorders . voice alteration . vulvovaginal disorders . weight
SIDE-EFFECTS, FURTHER INFORMATION Withdraw if
virilisation effects occur—may be irreversible on continued
l CONCEPTION AND CONTRACEPTION Ensure patients with
amenorrhoea are not pregnant. Non-hormonal
contraceptive methods should be used, if appropriate.
l PREGNANCY Avoid; has weak androgenic effects and
virilisation of female fetus reported.
l BREAST FEEDING No data available but avoid because of
possible androgenic effects in infant.
l HEPATIC IMPAIRMENT Manufacturer advises caution; avoid
l RENAL IMPAIRMENT Caution in renal impairment (avoid if
l MONITORING REQUIREMENTS Manufacturer advises
periodic monitoring of hepatic function and
haematological state (including biannual hepatic
ultrasonography for treatment exceeding 6 months or
repeated courses of treatment).
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug. Forms available
from special-order manufacturers include: capsule
Danazol 100 mg Danazol 100mg capsules | 28 capsule P £18.40
7.64e Danazol 200mg capsules | 56 capsule P
Danazol 100 mg Danol 100mg capsules | 60 capsule P £
16.38e Danol 200mg capsules | 60 capsule P £32.43e
Hypothalamic and anterior pituitary
Tetracosactide p. 744 (tetracosactrin), an analogue of
corticotropin (ACTH), is used to test adrenocortical function;
failure of the plasma cortisol concentration to rise after
administration of tetracosactide indicates adrenocortical
Both corticotropin and tetracosactide were formerly used
as alternatives to corticosteroids in conditions such as
Crohn’s disease; their value was limited by the variable and
unpredictable therapeutic response and by the waning of
Follicle-stimulating hormone (FSH) and luteinising hormone
(LH) together, or follicle-stimulating hormone alone (as in
follitropin), are used in the treatment of infertility in
women with proven hypopituitarism or who have not
responded to clomifene citrate p. 766, or in superovulation
treatment for assisted conception (such as in vitro
The gonadotrophins are also occasionally used in the
treatment of hypogonadotrophic hypogonadism and
associated oligospermia. There is no justification for their
use in primary gonadal failure.
Growth hormone is used to treat deficiency of the hormone
insufficiency, short children considered small for gestational
age at birth, and short stature homeobox-containing gene
Growth hormone of human origin (HGH; somatotrophin)
has been replaced by a growth hormone of human sequence,
somatropin p. 748, produced using recombinant DNA
adolescents with severe primary insulin-like growth factor-I
Gonadorelin p. 744 when injected intravenously in normal
subjects leads to a rapid rise in plasma concentrations of
both luteinising hormone (LH) and follicle-stimulating
hormone (FSH). It has not proved to be very helpful,
BNF 78 Hypothalamic and anterior pituitary hormone related disorders 743
however, in distinguishing hypothalamic from pituitary
lesions. Gonadorelin analogues are indicated in
endometriosis and infertility and in breast and prostate
PITUITARY AND HYPOTHALAMIC HORMONES
AND ANALOGUES › CORTICOTROPHINS
Diagnosis of adrenocortical insufficiency (diagnostic
▶ BY INTRAVENOUS INJECTION, OR BY INTRAMUSCULAR
▶ Adult: 250 micrograms for 1 dose
Diagnosis of adrenocortical insufficiency (diagnostic
▶ BY INTRAMUSCULAR INJECTION USING DEPOT INJECTION
Alternative to corticosteroids in conditions such as
Crohn’s disease or rheumatoid arthritis (formerly used
but value was limited by the variable and unpredictable
therapeutic response and by the waning of effect with
▶ BY INTRAMUSCULAR INJECTION USING DEPOT INJECTION
▶ Adult: Initially 1 mg daily, alternatively initially 1 mg
every 12 hours, (in acute cases), then reduced to 1 mg
every 2–3 days, followed by 1 mg once weekly,
alternatively 500 micrograms every 2–3 days
l CONTRA-INDICATIONS Acute psychosis . adrenogenital
syndrome . allergic disorders . asthma . avoid injections
containing benzyl alcohol in neonates . Cushing’s
syndrome . infectious diseases . peptic ulcer. primary
adrenocortical insufficiency .refractory heart failure
l CAUTIONS Active infectious diseases (should not be used
adequate disease-specific therapy is being given). diabetes
mellitus . diverticulitis . history of asthma . history of
amoebiasis (may become activated). latent tuberculosis
(may become activated). myasthenia gravis . ocular herpes
intestinal anastomosis .reduced immune response (should
not be used unless adequate disease-specific therapy is
being given). ulcerative colitis
▶ Risk of anaphylaxis Should only be administered under
medical supervision. Consult product literature.
▶ Hypertension Patients already receiving medication for
moderate to severe hypertension must have their dosage
adjusted if treatment started.
▶ Diabetes mellitus Patients already receiving medication for
diabetes mellitus must have their dosage adjusted if
exophthalmos . fluid retention . flushing . gastrointestinal
rupture .thromboembolism . vasculitis necrotising . vertigo . vomiting . weight increased
l ALLERGY AND CROSS-SENSITIVITY Contra-indicated in
patients with history of hypersensitivity to
tetracosactide/corticotrophins or excipients.
l PREGNANCY Avoid (but may be used diagnostically if
l BREAST FEEDING Avoid (but may be used diagnostically if
l HEPATIC IMPAIRMENT For depot injection, manufacturer
advises caution in cirrhosis (may enhance effect of
l RENAL IMPAIRMENT Use with caution in patients with
l EFFECT ON LABORATORY TESTS May suppress skin test
Post administration total plasma cortisol levels during
30-minute test for diagnosis of adrenocotical insufficiency
might be misleading due to altered cortisol binding
globulin levels in some special clinical situations
including, patients on oral contraceptives, post-operative
patients, critical illness, severe liver disease and nephrotic
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
▶ Synacthen (Mallinckrodt Specialty Pharmaceuticals Ireland Ltd)
Tetracosactide acetate 250 microgram per 1 ml Synacthen
250micrograms/1ml solution for injection ampoules | 1 ampoule P £38.00 DT = £38.00
EXCIPIENTS: May contain Benzyl alcohol
▶ Synacthen Depot (Mallinckrodt Specialty Pharmaceuticals Ireland
Tetracosactide acetate 1 mg per 1 ml Synacthen Depot 1mg/1ml
suspension for injection ampoules | 1 ampoule P £346.28 DT =
PITUITARY AND HYPOTHALAMIC HORMONES
AND ANALOGUES › GONADOTROPIN-RELEASING
(Gonadotrophin-releasing hormone; GnRH; LH–
Assessment of pituitary function
▶ BY SUBCUTANEOUS INJECTION, OR BY INTRAVENOUS INJECTION
▶ Adult: 100 micrograms for 1 dose
744 Hypothalamic and anterior pituitary hormone related disorders BNF 78
▶ Uncommon Pain . skin reactions . swelling
▶ Frequency not known Menorrhagia . sepsis . thrombophlebitis
l MEDICINAL FORMS No licensed medicines listed.
(Human chorionic gonadotropin)
Treatment of infertility in women with proven
hypopituitarism or who have not responded to clomifene
| Superovulation treatment for assisted conception (such
▶ Adult (female): Adjusted according to response.
malignancy . mammary malignancy . ovarian enlargement
l CAUTIONS Acute porphyrias p. 1058
▶ Uncommon Breast pain . depression . diarrhoea . irritability .restlessness
▶ Rare or very rare Rash . shock .thromboembolism
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
▶ Ovitrelle (Merck Serono Ltd)
Choriogonadotropin alfa 500 microgram per 1 ml Ovitrelle
250micrograms/0.5ml solution for injection pre-filled syringes | 1 preOvitrelle
P.5ml solution for injection pre-filled pen
| 1 pre-filled disposable injection P £37.66 DT = £37.66e
(Recombinant human follicle stimulating
Infertility in women with proven hypopituitarism or who
have not responded to clomifene | Superovulation
treatment for assisted conception (such as in vitro
▶ Adult (female): Adjusted according to response.
Hypogonadotrophic hypogonadism
▶ Adult (male): (consult product literature).
l CONTRA-INDICATIONS Ovarian cysts (not caused by
polycystic ovarian syndrome). ovarian enlargement (not
l CAUTIONS Acute porphyrias p. 1058 . history of tubal
▶ Common or very common Acne . diarrhoea . gastrointestinal
discomfort. gynaecomastia . headache . nausea . ovarian
and fallopian tube disorders . varicocele . vomiting . weight
▶ Rare or very rare Asthma exacerbated .thromboembolism
l PRESCRIBING AND DISPENSING INFORMATION Follitropin
alfa is a biological medicine. Biological medicines must be
prescribed and dispensed by brand name, see Biological
medicines and Biosimilar medicines, under Guidance on
Conception and contraception Patients planning to
conceive should be warned that there is a risk of multiple
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
▶ Bemfola (Gedeon Richter (UK) Ltd) A
Follitropin alfa 600 unit per 1 ml Bemfola 225units/0.375ml
solution for injection pre-filled pen | 1 pre-filled disposable
Follitropin alfa 600 unit per 1 ml Gonal-f 900units/1.5ml solution
for injection pre-filled pen | 1 pre-filled disposable injection P £338.40
▶ Ovaleap (Theramex HQ UK Ltd)
Follitropin alfa 600 unit per 1 ml Ovaleap 450units/0.75ml solution
for injection cartridges | 1 cartridge P £112.80
Ovaleap 900units/1.5ml solution for injection cartridges | 1 cartridge P £225.60
Ovaleap 300units/0.5ml solution for injection cartridges |
Powder and solvent for solution for injection
Follitropin alfa 75 unit Gonal-f 75unit powder and solvent for
solution for injection vials | 1 vial P £25.22
Follitropin alfa 450 unit Gonal-f 450unit powder and solvent for
solution for injection vials | 1 vial P £151.32
Follitropin alfa 1050 unit Gonal-f 1,050unit powder and solvent for
solution for injection vials | 1 vial P £353.06
BNF 78 Gonadotrophin replacement therapy 745
Follitropin alfa with lutropin alfa
The properties listed below are those particular to the
combination only. For the properties of the components
please consider, follitropin alfa p. 745, lutropin alfa below.
Infertility in women with proven hypopituitarism or who
have not responded to clomifene | Superovulation
treatment for assisted conception (such as in vitro
▶ Adult (female): Adjusted according to response.
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
Powder and solvent for solution for injection
ELECTROLYTES: May contain Sodium
▶ Pergoveris (Merck Serono Ltd)
Lutropin alfa 75 unit, Follitropin alfa 150 unit Pergoveris
150unit/75unit powder and solvent for solution for injection vials |
l DRUG ACTION Follitropin delta is a recombinant human
follicle stimulating hormone, which causes development
Superovulation treatment for assisted conception (such
as in vitro fertilisation) (initiated under specialist
▶ Adult (female): Initial dosing based on serum antiMüllerian hormone concentration and body-weight—
l CONTRA-INDICATIONS Ovarian cysts (not caused by
polycystic ovarian syndrome). ovarian enlargement (not
of pituitary .tumours of uterus . vaginal bleeding of
l CAUTIONS Acute porphyrias p. 1058 . history of tubal
disease (increased risk of ectopic pregnancy)
swings . vaginal haemorrhage . vomiting
▶ Rare or very rare Thromboembolism
SIDE-EFFECTS, FURTHER INFORMATION If ovarian
hyperstimulation syndrome occurs, the patient should be
advised to withhold hCG and avoid intercourse or use
barrier contraceptive methods for at least 4 days.
l PREGNANCY Manufacturer advises avoid—not indicated
l BREAST FEEDING Manufacturer advises avoid—not
indicated during breastfeeding.
l MONITORING REQUIREMENTS Manufacturer advises
regular monitoring of ovarian response with ultrasound
alone, or in combination with serum estradiol levels.
Frequent monitoring of follicular development is required
to reduce the risk of ovarian hyperstimulation syndrome
during treatment, and for at least 2 weeks after triggering
of final follicular maturation—consult product literature.
l DIRECTIONS FOR ADMINISTRATION Manufacturer
recommends the cartridge should be used with the
Rekovelle ® injection pen. The first injection should be
are well motivated, adequately trained and have access to
l PRESCRIBING AND DISPENSING INFORMATION Follitropin
delta is a biological medicine. Biological medicines must
be prescribed and dispensed by brand name, see Biological
medicines and Biosimilar medicines, under Guidance on
l HANDLING AND STORAGE Manufacturer advises store in a
refrigerator (2–8 °C)—consult product literature for
further information regarding storage conditions outside
Conception and contraception Manufacturer advises that
patients planning to conceive should be warned that there
is a risk of multiple pregnancy.
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
▶ Rekovelle (Ferring Pharmaceuticals Ltd) A
Follitropin delta 33.33 microgram per 1 ml Rekovelle
12micrograms/0.36ml solution for injection cartridges | 1 cartridge P £118.31
Rekovelle 36micrograms/1.08ml solution for injection cartridges | 1 cartridge P £354.94
Rekovelle 72micrograms/2.16ml solution for injection cartridges |
(Recombinant human luteinising hormone)
Treatment of infertility in women with proven
hypopituitarism or who have not responded to clomifene
(in conjunction with follicle-stimulating hormone)|
Superovulation treatment for assisted conception (such
as in vitro fertilisation) (in conjunction with folliclestimulating hormone)
▶ Adult (female): Adjusted according to response.
l CONTRA-INDICATIONS Mammary carcinoma . ovarian
carcinoma . ovarian enlargement or cyst (unless caused by
l CAUTIONS Acute porphyrias p. 1058
and fallopian tube disorders . pelvic pain . vomiting
▶ Rare or very rare Thromboembolism
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
Powder and solvent for solution for injection
Lutropin alfa 75 unit Luveris 75unit powder and solvent for solution
for injection vials | 1 vial P £31.38
746 Hypothalamic and anterior pituitary hormone related disorders BNF 78
Infertility in women with proven hypopituitarism or who
have not responded to clomifene | Superovulation
treatment for assisted conception (such as in vitro
▶ BY SUBCUTANEOUS INJECTION, OR BY DEEP INTRAMUSCULAR
▶ Adult (female): Adjusted according to response.
Hypogonadotrophic hypogonadism
▶ BY DEEP INTRAMUSCULAR INJECTION, OR BY SUBCUTANEOUS
▶ Adult (male): (consult product literature).
l CONTRA-INDICATIONS Ovarian cysts (not caused by
polycystic ovarian syndrome). ovarian enlargement (not
l CAUTIONS Acute porphyrias p. 1058 . history of tubal
▶ Uncommon Deep vein thrombosis
l PRESCRIBING AND DISPENSING INFORMATION
Menotrophin is purified extract of human postmenopausal urine containing follicle-stimulating
hormone (FSH) and luteinising hormone (LH) in a ratio of
Conception and contraception Patients planning to
conceive should be warned that there is a risk of multiple
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
Powder and solvent for solution for injection
▶ Menopur (Ferring Pharmaceuticals Ltd)
Menotrophin 75 unit Menopur 75unit powder and solvent for
solution for injection vials | 10 vial P £180.18 DT = £180.18
Menotrophin 150 unit Menopur 150unit powder and solvent for
solution for injection vials | 10 vial P £360.36 DT = £360.36
Menotrophin 600 unit Menopur 600unit powder and solvent for
solution for injection vials | 1 vial P £144.14 DT = £144.14
Menotrophin 1200 unit Menopur 1,200unit powder and solvent for
solution for injection vials | 1 vial P £288.29 DT = £288.29
▶ Meriofert (Pharmasure Ltd) A
Menotrophin 75 unit Meriofert 75unit powder and solvent for
solution for injection vials | 10 vial P £279.00 DT = £180.18
Menotrophin 150 unit Meriofert 150unit powder and solvent for
solution for injection vials | 10 vial P £558.00 DT = £360.36
Menotrophin 75 unit Merional 75unit powder and solvent for
solution for injection vials | 10 vial P £279.00 DT = £180.18
Menotrophin 150 unit Merional 150unit powder and solvent for
solution for injection vials | 10 vial P £558.00 DT = £360.36
Infertility in women with proven hypopituitarism or who
have not responded to clomifene | Superovulation
treatment for assisted conception (such as in vitro
▶ BY SUBCUTANEOUS INJECTION, OR BY DEEP INTRAMUSCULAR
▶ Adult (female): Adjusted according to response.
l CONTRA-INDICATIONS Ovarian cysts (not caused by
polycystic ovarian syndrome).tumours of breast.tumours
l CAUTIONS Acute porphyrias p. 1058
l PRESCRIBING AND DISPENSING INFORMATION
Urofollitropin is purified extract of human postmenopausal urine containing follicle-stimulating
Conception and contraception Patients planning to
conceive should be warned that there is a risk of multiple
l MEDICINAL FORMS There can be variation in the licensing of
different medicines containing the same drug.
Powder and solvent for solution for injection
Follicle stimulating hormone human (as Urofollitropin)
75 unit Fostimon 75unit powder and solvent for solution for injection
Follicle stimulating hormone human (as Urofollitropin)
150 unit Fostimon 150unit powder and solvent for solution for
injection vials | 10 vial P £558.00
Other drugs used for Growth hormone disorders
PITUITARY AND HYPOTHALAMIC HORMONES
AND ANALOGUES › GROWTH HORMONE
l DRUG ACTION Pegvisomant is a genetically modified
analogue of human growth hormone and is a highly
selective growth hormone receptor antagonist.
Treatment of acromegaly in patients with inadequate
response to surgery, radiation, or both, and to treatment
with somatostatin analogues (initiated by a specialist)
▶ Adult: Initially 80 mg for 1 dose, followed by 10 mg
daily, then increased in steps of 5 mg daily, adjusted
according to response; maximum 30 mg per day
l CAUTIONS Abnormal liver function tests and/or signs or
symptoms of liver injury (further investigations may be
Comments
Post a Comment
اكتب تعليق حول الموضوع